This roundup of recent amyotrophic lateral sclerosis (ALS) research and clinical trials news includes:
This roundup of recent MDA-supported amyotrophic lateral sclerosis (ALS) research news and reviews includes:
The U.S. Food and Drug Administration (FDA) has given the go-ahead to the nonprofit biotech ALS Therapy Development Institute (ALS TDI) to conduct a clinical trial of TDI132 — also known as fingolimod, or the brand name Gilenya— in people withALS (amyotrophic lateral sclerosis).
A 40-person phase 2 clinical trial to test the safety and tolerability of Questcor Pharmaceuticals’ H.P. Acthar Gel (Acthar) in people with amyotrophic lateral sclerosis (ALS) has opened at a trial site in Phoenix, Ariz.
Muscular Dystrophy Association — USA
National Office222 S. Riverside Plaza, Suite 1500
Chicago, Illinois 60606(800) 572-1717
The Muscular Dystrophy Association (MDA) is a qualified 501(c)(3) tax-exempt organization.
©2014, Muscular Dystrophy Association Inc. All rights reserved.